Abstract: Liposomal spherical nucleic acids that function as multivalent immune modulators are provided according to the invention. The liposomal spherical nucleic acids of the invention are useful prophylactic and therapeutic applications as well as research and diagnostic indications.
Type:
Grant
Filed:
August 18, 2021
Date of Patent:
April 16, 2024
Assignee:
Exicure Operating Company
Inventors:
Aleksandar Filip Radovic-Moreno, Richard Kang, Subbarao Nallagatla, Christopher C. Mader, Sergei Gryaznov
Abstract: Aspects of the invention relate to antisense oligonucleotides directed to the interleukin 17 receptor (IL-17R), and other targets. Spherical nucleic acid formulations or compositions of antisense oligonucleotides and related methods of treatment are also provided.
Type:
Grant
Filed:
May 5, 2017
Date of Patent:
January 9, 2024
Assignee:
Exicure Operating Company
Inventors:
Richard Kang, Scott Mix, Ekambar Kandimalla
Abstract: Provided herein are compositions and methods for inhibiting the expression and/or activity of kallikrein-related peptidase (KLK) (e.g., KLK5 and KLK7) genes and/or KLK (e.g., KLK5 and KLK7) gene products using oligonucleotide-based therapy. In some embodiments, the compositions are spherical nucleic acids (SNAs) targeting a region of a KLK5 gene and/or gene product and a second synthetic oligonucleotide targeting a region of a KLK7 gene and/or a KLK7 gene product. Such compositions and methods are useful, for instance, in the treatment, prevention, and/or amelioration of diseases or disorders associated with the dysregulation of KLK function.
Abstract: Aspects of the disclosure relate to the administration of at least one of spherical nucleic acids (SNAs), a checkpoint inhibitor antibody, and an agonist of a tumor necrosis factor receptor superfamily (TNFRSF) member at various doses, schedules of administration, orders of administration, etc. for treatment of a disease, such as cancer.
Abstract: Spherical nucleic acids (SNA) carrying self-aggregating oligonucleotides are described herein. Compositions of the SNA include discrete nanostructures that are not aggregated. Related methods are also described.
Type:
Grant
Filed:
April 27, 2018
Date of Patent:
July 11, 2023
Assignee:
Exicure Operating Company
Inventors:
Richard Kang, Subbarao Nallagatla, Bart Anderson, Ekambar Kandimalla
Abstract: The present application is directed to the intravitreal use of spherical nucleic acid (SNA) molecules in the treatment of eye disorders including dry-eye, retinal edema, retinopathy, macular degeneration and glaucoma among others. SNAs have a liposomal core with a plurality of oligonucleotides on the surface forming a shell, wherein the oligonucleotide preferably a TNF-alpha antisense oligonucleotide.
Abstract: Compositions related to spherical nucleic acids (SNAs) with antisense oligonucleotides and methods of treatment of diseases and disorders are disclosed therein. In particular, the antisense oligonucleotides are targeted to a region in a pre-mRNA of interest to regulate pre-mRNA splicing.
Abstract: Liposomal spherical nucleic acids that function as multivalent immune modulators are provided according to the invention. The liposomal spherical nucleic acids of the invention are useful prophylactic and therapeutic applications as well as research and diagnostic indications.
Type:
Application
Filed:
August 18, 2021
Publication date:
August 18, 2022
Applicant:
Exicure Operating Company
Inventors:
Aleksandar Filip Radovic-Moreno, Richard Kang, Subbarao Nallagatla, Christopher C. Mader, Sergei Gryaznov
Abstract: Aspects of the invention are directed to methods of treating cancer using a combination of spherical nucleic acids (SNAs) and a checkpoint inhibitor. The SNA molecule comprises a core oligonucleotide shell of CpG oligonucleotides positioned on the exterior of this core. The SNA is administered at a fixed dose of 2mg to a solid tumour or tumour lesion, and is administered within 24 hours of the checkpoint inhibitor administration. The SNA can also be administered at a dose of 700 mg-900 mg every 2 weeks. The SNA can also be a CpG linked via a spacer to the exterior surface of a liposome core of 40 nm or less diameter.
Type:
Application
Filed:
February 12, 2020
Publication date:
March 24, 2022
Applicant:
Exicure Operating Company
Inventors:
Pinal Patel, Weston Daniel, Alice Bexon, Matthias Schroff
Abstract: Liposomal spherical nucleic acids that function as multivalent immune modulators are provided according to the invention. The liposomal spherical nucleic acids of the invention are useful prophylactic and therapeutic applications as well as research and diagnostic indications.
Type:
Grant
Filed:
September 12, 2019
Date of Patent:
September 21, 2021
Assignee:
Exicure Operating Company
Inventors:
Aleksandar Filip Radovic-Moreno, Richard Kang, Subbarao Nallagatla, Christopher C. Mader, Sergei Gryaznov